Showing 581-590 of 6934 results for "".
Buyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.2018 Therapeutics and Device Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2018-therapeutics-and-device-highlights/18374/2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.DermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlookDermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic derNew Hope for the Hopeless
https://practicaldermatology.com/issues/august-2025/new-hope-jak-inhibitors-alopecia/36693/Dr. Elizabeth (Lisa) Swanson, a dermatologist and associate medical editor of Practical Dermatology, looks at the critical role of case reports in developing new therapeutic options for patients.Drs. Rosen and Bhatia Highlight Latest Drugs at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/drs-rosen-and-bhatia-highlight-latest-drugs-at-maui-derm/32914/The current landscape of therapeutics for dermatologic conditions is dramatic, with new groundbreaking drugs continuously becoming available.Jet Assisted Fat Transfer on Face and Hands
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/jet-assisted-fat-transfer-on-face-and-hands/19391/LIVE Patient DemonstrationHow to Choose the Right Filler
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-to-choose-the-right-filler/19411/Dr. Amy Derick reviews key points about injectable fillers, a non-invasive alternative to surgical facelifts.DermwireTV: DermaRite Issues Recall for Several Hand Soaps
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermarite-issues-recall-for-several-hand-soaps/37113/In this episode, new research shows switching between interclass biologics may be safe and effective for psoriasis patients; DermaRite recalls 4 skin care products over contamination concerns; and awareness grows for generalized pustular psoriasis through a new global awareness campaign.Atypical Sweet Syndrome: A Case Report and Brief Literature Review
https://practicaldermatology.com/topics/rare-disease/atypical-sweet-syndrome-a-case-report-and-brief-literature-review/23610/A case highlights the complexity of this diagnosis, including its management and workup, especially when pathology findings are atypical.